North America Cancer Biopsy Market Insights Forecasts to 2033

• The North America Cancer Biopsy Market Size was valued at USD 10.23 Billion in 2023.
• The Market is Growing at a CAGR of 10.1% from 2023 to 2033
• The North America Cancer Biopsy Market Size is Expected to Reach USD 26.78 Billion by 2033

The North America Cancer Biopsy Market Size is Anticipated to Reach USD 26.78 Billion by 2033, Growing at a CAGR of 10.1 from 2023 to 2033.

Market Overview

Cancer Biopsy refers to the methods and techniques employed to detect and identify the presence of cancer in an individual. The goal of cancer biopsy is to identify abnormalities in cells or tissues that may indicate the development of cancerous growths. These diagnostic methods encompass a wide range of approaches, including medical imaging, laboratory tests, and molecular analysis. Common diagnostic tools include X-rays, CT scans, MRIs, biopsies, blood tests, and genetic testing. Early and accurate detection of cancer is crucial for effective treatment and improved prognosis. Advancements in technology and research have led to the development of more precise and personalized diagnostic methods, enhancing the ability to detect cancer at earlier stages and tailor treatment plans to individual patients. Cancer Biopsy plays a pivotal role in the overall management of cancer, facilitating timely interventions and contributing to better outcomes for patients. With cancer rates increasing, there is an urgent need for precise diagnostics to enable timely and accurate detection, allowing appropriate treatment strategies to be implemented.

Report Coverage

This research report categorizes for the North America cancer biopsy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America cancer biopsy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America cancer biopsy market.

Driving Factors

The North American cancer biopsy market is expected to grow significantly over the forecast period, owing primarily to an increase in cancer incidence in the United States. According to John Wiley & Sons, Inc.'s 2024 data, the American Cancer Society predicts an alarming increase in new cancer cases and deaths in the United States. Their estimates predict 2,001,140 new cancer cases and 611,720 cancer-related deaths in 2024. This data highlights the critical need for advanced and efficient cancer biopsy tools and technologies to address the country's rising cancer burden. The statistics emphasize the importance of accurate and timely diagnosis in disease management, which drives demand for innovative diagnostic solutions. This increase in cancer cases is expected to be a major driver of growth in the North American cancer biopsy market, as healthcare providers and researchers seek innovative solutions to improve early detection, prognosis, and treatment outcomes in the face of an escalating health crisis.

Restraining Factors

The growing prevalence of cancer misinformation is a microcosm of the larger problem of scientific misinformation, which, despite its prevalence, is poorly understood by the general public. These concerns and misinformation can impede the adoption of new cancer diagnostic technologies in North America.

Market Segmentation

The North America cancer biopsy market share is classified into product and type

• The kits and consumables segment is expected to hold the largest market share through the forecast period.

The North America cancer biopsy market is segmented by product into instruments, kits and consumables, and services. Among these, the kits and consumables segment is expected to hold the largest market share through the forecast period. This can be attributed to the important role these components play in the biopsy procedure. Biopsy kits and consumables, such as needles and reagents, are required for collecting and analyzing tissue samples, which results in accurate cancer diagnosis. Large investments by major industry players have contributed significantly to the segment's growth.

• The liquid biopsy segment is expected to dominate the North America cancer biopsy market during the forecast period.       

Based on the type, the North America cancer biopsy market is divided into tissue biopsy, surgical biopsy, liquid biopsy, and others. Among these, the liquid biopsy segment is expected to dominate the North America cancer biopsy market during the forecast period. Liquid biopsies have transformed clinical oncology by offering a minimally invasive method for tumor identification, screening, early detection of recurrence, and personalized treatment regimens. The benefits of liquid biopsy, such as lower costs, early prognosis, therapy monitoring, and patient comfort, have significantly increased its adoption and market share.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America cancer biopsy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• lllumina Inc
• BD (Becton, Dickinson, and Company)
• Myriad Genetics Inc.
• Thermo Fisher Scientific
• BIOCEPT INC.
• Hologic Inc
• Danaher
• Agilent Technologies Inc.
• IZI Medical
• Johnson & Johnson Services, Inc.
• Medtronic
• Boston Scientific Corporation
• VESICA HEALTH, INC.
• CONMED Corporation
• INRAD, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2024, VESICA HEALTH, INC., a liquid biopsy company specializing in hematuria management and early bladder cancer detection, launched the laboratory-developed AssureMDx test. AssureMDx represents a significant advancement in bladder cancer diagnostics, providing exceptional accuracy and reliability based on extensive scientific validation. This ground-breaking test demonstrates Vesica Health's unwavering commitment to raising the standard of care for hematuria patients worldwide.

Market Segment

This study forecasts revenue at North America, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the North America cancer biopsy market based on the below-mentioned segments:

North America Cancer Biopsy Market, By Product

• Instruments
• Kits and Consumables
• Services

North America Cancer Biopsy Market, By Type

• Tissue Biopsy
• Surgical Biopsy
• Liquid Biopsy
• Others